ISDA

Entry Detail

PDB ID:

8FH4

Keywords:

Title:

Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-[6-chloro-4-(9-methyl-1-oxa-4,9-diazaspiro[5.5]undec-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2022-12-13

Release Date:

2023-04-05

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.83 Å

R-Value Free:

0.21

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Mitogen-activated protein kinase kinase kinase kinase 1
Mutations:T165E, S171E
Chain IDs:A, B, C, D
Chain Length:331
Number of Molecules:4
Biological Source:Homo sapiens

UniProt ID:Q92918 Pfam ID:PF00069

Ligand Molecules

SO4

XXF

Primary Citation

Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1.

Gallego, R.A, Bernier, L, Chen, H, Cho-Schultz, S, Chung, L, Collins, M, Del Bel, M, Elleraas, J, Costa Jones, C, Cronin, C.N, Edwards, M, Fang, X, Fisher, T, He, M, Hoffman, J, Huo, R, Jalaie, M, Johnson, E, Johnson, T.W, Kania, R.S, Kraus, M, Lafontaine, J, Le, P, Liu, T, Maestre, M, Matthews, J, McTigue, M, Miller, N, Mu, Q, Qin, X, Ren, S, Richardson, P, Rohner, A, Sach, N, Shao, L, Smith, G, Su, R, Sun, B, Timofeevski, S, Tran, P, Wang, S, Wang, W, Zhou, R, Zhu, J, Nair, S.K.Show

J.Med.Chem. 66 4888 4909 (2023)

PMID: 36940470 DOI: 10.1021/acs.jmedchem.2c02038

Abstact

Immune activating agents represent a valuable class of therapeutics for the treatment of cancer. An area of active research is expanding the types of these therapeutics that are available to patients via targeting new biological mechanisms. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of immune signaling and a target of high interest for the treatment of cancer. Herein, we present the discovery and optimization of novel amino-6-aryl pyrrolopyrimidine inhibitors of HPK1 starting from hits identified via virtual screening. Key components of this discovery effort were structure-based drug design aided by analyses of normalized B-factors and optimization of lipophilic efficiency.

Legend

Protein

Chemical

Disease

Primary Citation of related structures